2d illustrations and photos/iStock via Getty Images HashiCorp (NASDAQ:HCP) and IBM (NYSE:IBM) have acknowledged the receipt of a second request for information from the Federal Trade Commission over its antitrust probe of their merger. IBM in late April agreed to buy HashiCorp for $35 a share in cash. The twoContinue Reading
LD The Federal Trade Commission (FTC) has launched an investigation into whether the nation’s largest dialysis providers, DaVita (NYSE:DVA) and Fresenius Medical Care (NYSE:FMS), are allegedly harming their small competitors, The Politico reported Saturday. Citing people familiar with the matter, the publication said that part of the probe focuses onContinue Reading
jetcityimage/iStock Editorial via Getty Images The Federal Trade Commission plans to delay its decision on whether to block Chevron’s (NYSE:CVX) takeover of Hess (HES) until after the arbitration case with Exxon Mobil (XOM) is settled, Bloomberg reported Thursday. The arbitration case with Exxon (XOM), which claims to have a rightContinue Reading
Sundry Photography/iStock Editorial via Getty Images HashiCorp (NASDAQ:HCP) edged lowed by almost 1% amid some investor concern that its planned sale to IBM (NYSE:IBM) will get a request for more information from antitrust regulators. Investors are worried that the Federal Trade Commission will issue a second request as a FridayContinue Reading
AndreyPopov The Federal Trade Commission’s lawsuit on Tuesday to block Tempur Sealy’s (NYSE:TPX) planned $4 billion purchase of Mattress Firm removes an overhang on Tempur Sealy’s stock, according to a Piper Sandler analyst. The regulator issued an administrative complaint and authorized a lawsuit in federal court to prevent the deal,Continue Reading
ewg3D/E+ via Getty Images CoStar (NASDAQ:CSGP) and Matterport (NASDAQ:MTTR) disclosed they received a request for more information from the Federal Trade Commission about their planned deal. The effect of the second request is to extend the waiting period of the HSR Act until 30 days after the companies have substantiallyContinue Reading
vzphotos/iStock Editorial via Getty Images Cerevel Therapeutics (NASDAQ:CERE) quickly fell 4% amid a report about the Federal Trade Commission’s review of its sale to AbbVie. The staff of the FTC’s Mergers 1 section is said to be apparently considering a recommendation to block the Cerevel (CERE) deal, according to aContinue Reading
Scott Olson/Getty Images News Vizio (NYSE:VZIO), which agreed to sell itself to Walmart (WMT) in February, edged lower by 1.2% as the Federal Trade Commission sued to block Tempur Sealy’s (TPX) sale to Mattress Firm. Earlier Tuesday, the FTC sued to block mattress maker Tempur Sealy’s (TPX) planned $4 billionContinue Reading
JHVEPhoto/iStock Editorial via Getty Images Update 1:20pm: Updates shares, adds Tempur Sealy response. The Federal Trade Commission sued to block mattress maker Tempur Sealy’s (NYSE:TPX) planned $4 billion purchase of retailer Mattress Firm. Tempur Sealy rose 2.4% The regulator issued an administrative complaint and authorized a lawsuit in federal courtContinue Reading
sergeyryzhov/iStock via Getty Images Cerevel Therapeutics (NASDAQ:CERE) rose 2.2% amid a report that the Federal Trade Commission’s closed door meeting on Monday is about Tempur Sealy’s (NYSE:TPX) proposed acquisition of Mattress Firm. Tempur Sealy ticked down 0.5%. The FTC closed-door meeting is expected to decide the fate of the MattressContinue Reading
